Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021
Treatment regimen patterns for HER2-positive BC evolved in correspondence with the U.S. Food and Drug Administration's approval of new drugs for this cancer and National Comprehensive Cancer Network treatment guidelines.
Authors
- Hui Zhao (ORCID: https://orcid.org/0000-0002-3710-3607)
- Sharon Hermes Giordano (ORCID: https://orcid.org/0000-0002-8700-2767)
- Chan Shen (ORCID: https://orcid.org/0000-0001-5680-3134)
- Jiangong Niu (ORCID: https://orcid.org/0000-0001-5643-5490)
- Xiudong Jennifer Lei (ORCID: https://orcid.org/0000-0002-5346-2992)
- Mariana Chavez-MacGregor
- Jaime J Laureano
Institutions
- Pennsylvania State University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1007/s10549-024-07552-y
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Susan G. Komen for the Cure
- Breast Cancer Research Foundation
- Cancer Prevention and Research Institute of Texas
- University of Texas MD Anderson Cancer Center